vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
SOLESENCE, INC. is the larger business by last-quarter revenue ($12.5M vs $8.1M, roughly 1.5× Arcellx, Inc.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -766.0%, a 767.3% gap on every dollar of revenue. On growth, SOLESENCE, INC. posted the faster year-over-year revenue change (-0.7% vs -79.3%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs -24.6%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
ACLX vs SLSN — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $12.5M |
| Net Profit | $-62.3M | $163.0K |
| Gross Margin | — | 27.5% |
| Operating Margin | -847.6% | 1.5% |
| Net Margin | -766.0% | 1.3% |
| Revenue YoY | -79.3% | -0.7% |
| Net Profit YoY | -765.1% | 129.2% |
| EPS (diluted) | $-1.13 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.5M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | — | $20.4M | ||
| Q1 25 | $8.1M | $14.6M | ||
| Q4 24 | $15.3M | $12.6M | ||
| Q3 24 | $26.0M | $16.9M | ||
| Q2 24 | $27.4M | $13.0M | ||
| Q1 24 | $39.3M | $9.9M |
| Q4 25 | — | $163.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | $-62.3M | $80.0K | ||
| Q4 24 | $-47.1M | $-559.0K | ||
| Q3 24 | $-25.9M | $3.0M | ||
| Q2 24 | $-27.2M | $856.0K | ||
| Q1 24 | $-7.2M | $893.0K |
| Q4 25 | — | 27.5% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 36.2% | ||
| Q2 24 | — | 28.7% | ||
| Q1 24 | — | 36.3% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | — | -5.4% | ||
| Q2 25 | — | 9.4% | ||
| Q1 25 | -847.6% | 1.8% | ||
| Q4 24 | -348.2% | -1.8% | ||
| Q3 24 | -129.1% | 19.0% | ||
| Q2 24 | -127.8% | 8.0% | ||
| Q1 24 | -40.3% | 11.3% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | -7.7% | ||
| Q2 25 | — | 13.1% | ||
| Q1 25 | -766.0% | 0.5% | ||
| Q4 24 | -308.4% | -4.4% | ||
| Q3 24 | -99.4% | 18.1% | ||
| Q2 24 | -99.3% | 6.6% | ||
| Q1 24 | -18.3% | 9.0% |
| Q4 25 | — | $0.00 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $0.04 | ||
| Q1 25 | $-1.13 | $0.00 | ||
| Q4 24 | $-0.87 | $0.00 | ||
| Q3 24 | $-0.48 | $0.04 | ||
| Q2 24 | $-0.51 | $0.01 | ||
| Q1 24 | $-0.14 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $416.9M | $17.6M |
| Total Assets | $648.1M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $429.0K | ||
| Q2 25 | — | $4.1M | ||
| Q1 25 | $543.3M | $1.8M | ||
| Q4 24 | $587.4M | $1.4M | ||
| Q3 24 | $574.3M | $2.9M | ||
| Q2 24 | $516.7M | $2.4M | ||
| Q1 24 | $573.9M | $2.0M |
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $17.2M | ||
| Q2 25 | — | $18.2M | ||
| Q1 25 | $416.9M | $15.2M | ||
| Q4 24 | $454.8M | $14.9M | ||
| Q3 24 | $483.0M | $15.2M | ||
| Q2 24 | $487.2M | $11.9M | ||
| Q1 24 | $496.6M | $5.0M |
| Q4 25 | — | $50.1M | ||
| Q3 25 | — | $54.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | $648.1M | $57.0M | ||
| Q4 24 | $711.3M | $50.0M | ||
| Q3 24 | $764.9M | $48.0M | ||
| Q2 24 | $734.3M | $40.8M | ||
| Q1 24 | $779.7M | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $1.8M |
| Free Cash FlowOCF − Capex | $-63.9M | — |
| FCF MarginFCF / Revenue | -786.4% | — |
| Capex IntensityCapex / Revenue | 9.6% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $-2.5M | ||
| Q2 25 | — | $-654.0K | ||
| Q1 25 | $-63.1M | $-7.2M | ||
| Q4 24 | $-46.0M | $2.2M | ||
| Q3 24 | $30.7M | $4.2M | ||
| Q2 24 | $-36.2M | $-565.0K | ||
| Q1 24 | $-31.9M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-63.9M | — | ||
| Q4 24 | $-47.5M | $-404.0K | ||
| Q3 24 | $28.4M | $2.8M | ||
| Q2 24 | $-39.5M | $-1.0M | ||
| Q1 24 | $-38.3M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -786.4% | — | ||
| Q4 24 | -311.3% | -3.2% | ||
| Q3 24 | 109.2% | 16.6% | ||
| Q2 24 | -144.1% | -8.0% | ||
| Q1 24 | -97.7% | -39.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 9.8% | 20.6% | ||
| Q3 24 | 8.8% | 8.3% | ||
| Q2 24 | 11.7% | 3.7% | ||
| Q1 24 | 16.4% | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
